{"url_path":"/sec/camp/8-k/2026-05-14/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1736730/0001736730-26-000033-index.html","accession_number":"0001736730-26-000033","cik":"0001736730","ticker":"CAMP","issuer_name":"Camp4 Therapeutics Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1736730/0001736730-26-000033-index.html","primary_entity_key":"0001736730","primary_entity_name":"Camp4 Therapeutics Corp"},"word_count":163,"has_tables":true,"body_markdown":"Item 7.01 Regulation FD Disclosure.\n\nOn May 14, 2026, CAMP4 Therapeutics Corporation (the “Company”) issued a press releases titled “CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder,” a copy of which is furnished as Exhibit 99.1 hereto.\n\nOn May 14, 2026, the Company also updated its corporate slide presentation, a copy of which is furnished as Exhibit 99.2 hereto.\n\nThe information in this Item 7.01 and Exhibits 99.1 and 99.2 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing."}